Results 111 to 120 of about 627,285 (279)

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim   +37 more
wiley   +1 more source

Creatine salts provide neuroprotection even after partial impairment of the creatine transporter

open access: yes, 2017
Creatine, a compound that is critical for energy metabolism of nervous cells, crosses the blood-brain barrier (BBB) and the neuronal plasma membrane with difficulty, and only using its specific transporter.
GARBATI, PATRIZIA   +5 more
core   +1 more source

An ETH‐LAD trip with unfavourable consequences: A case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH‐LAD (6‐ethyl‐6‐nor‐lysergic acid diethylamide), the N‐ethyl derivative of LSD.
Johannes Nadler   +6 more
wiley   +1 more source

Successful management of refractory epilepsy in creatine transporter deficiency with cannabidiol and clobazam: A case report

open access: yesEpilepsia Open
Creatine transporter deficiency (CRTR‐D) is a rare X‐linked inherited disease belonging to the group of cerebral creatine deficiency disorders. Major clinical features include developmental delay and epilepsy.
Maria Borrell‐Pichot   +3 more
doaj   +1 more source

Rocavorexant, a novel, selective orexin‐1 receptor antagonist: Safety, tolerability and pharmacokinetics in healthy adults and individuals with opioid use disorder

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Rocavorexant (INDV‐2000), a selective orexin‐1 receptor antagonist, reduces drug self‐administration and anxiety in nonclinical studies. This Phase 1 programme evaluated the safety, pharmacokinetics and pharmacodynamics of rocavorexant in healthy volunteers and treatment‐seeking individuals with opioid use disorder (OUD).
Martin Kankam   +5 more
wiley   +1 more source

Mitochondria‐endoplasmic reticulum organelle glue as maturation promoter for origination/dimensional dual‐cross cardiomyocytes

open access: yesBMEMat, EarlyView.
Mitochondria‐endoplasmic reticulum contact sites (MERCS) are areas where the mitochondria and endoplasmic reticulum closely interact. In this study, we utilize synthetic organelle glues to artificially engineer MERCS for regulating cardiomyocyte development, through which the immature and chemo‐plasticity issues of undifferentiated cells are addressed.
Wei Tang   +9 more
wiley   +1 more source

Channel‐trap coupled charge modulation in sulfur‐vacancy‐rich nanotransducer for enhanced dual‐mode cancer catalytic therapy

open access: yesBMEMat, EarlyView.
Sulfur vacancy‐rich ZnS–NCx heterojunctions are engineered as dual‐function nanotransducers, in which channel‐trap‐coupled electronic pathways enable efficient capture and transport of ultrasound‐induced piezoelectrons. This vacancy‐mediated regulation simultaneously enhances sonodynamic activity and biomimetic POD/GSHOx catalysis, triggering a self ...
Songjing Zhong   +10 more
wiley   +1 more source

Outcome of creatine supplementation therapy in phosphoglucomutase-1 deficiency associated congenital disorders of glycosylation: Novel insights

open access: yesMolecular Genetics and Metabolism Reports
Background: Biallelic pathogenic variants in PGM1 result in phosphoglucomutase 1 (PGM1) deficiency that is one of the congenital disorders of glycosylation (CDG) (PGM1-CDG).
Anastasia Ambrose   +5 more
doaj   +1 more source

Creatine transporter-deficient rat model shows motor dysfunction, cerebellar alterations, and muscle creatine deficiency without muscle atrophy. [PDF]

open access: yesJ Inherit Metab Dis, 2022
Duran-Trio L   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy